Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herbal remedy may speed bronchitis recovery

NCT ID NCT05916768

Symptom relief Sponsor: University of Fribourg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a herbal extract called Pelargonium sidoides (EPs®7630) helps adults with acute bronchitis recover faster and need fewer antibiotics. Over 300 participants in Switzerland were randomly assigned to receive the extract or usual care. The main goal was to see how quickly symptoms improved and whether antibiotic use decreased.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

332 people

The number who actually took part.

Started

May 2023

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (aged 18 and over) consulting for the first time, for the same episode, either for an acute cough (≤8 days) as the main symptom, suggestive of acute bronchitis, or for an illness (≤8 days) in which cough is not the main symptom but PCP believes that acute bronchitis is the most likely diagnosis. * Patients tested positive to COVID-19 who meet the above-mentioned criteria will be included too. Exclusion Criteria: * Infection requiring antibiotic treatment (ex. cystic fibrosis) * Pneumonia * Known hypersensitivity to Pelargonium sidoides extract or excipients of the trial medication * Non-infectious causes (COPD, asthma, pulmonary embolism, heart failure, gastroesophageal reflux, allergy) * Lacking the faculty of discernment (for example: dementia, decompensated psychosis or severe depression) * Inability to fill out the diary (no ability to read and understand French) * Pregnancy or breastfeeding * Immunological deficiencies * Hospitalization * Severe hepatic disease * Patients who have already started a treatment with Pelargonium sidoides EPs® 7630 for this current episode (Kaloba®, Umckaloabo®) * Important risk of bleeding (severe thrombocytopenia and anticoagulant intake) * If the patient is taking a drug among these classes of drugs: anticoagulants, immunosuppressants, chemotherapy or immunotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute bronchitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute bronchitis

Contacts and locations

Locations

  • University of Fribourg

    Fribourg, Canton of Fribourg, 1700, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.